MK-677 prescription FAQ — regulatory status and access outlook.
Is MK-677 a SARM? What is its FDA regulatory status? Could it become available by prescription? How does Category 2 classification affect access? Everything patients and researchers ask about MK-677 regulatory and prescription questions.
Is MK-677 a SARM?
No. MK-677 (ibutamoren) is not a selective androgen receptor modulator (SARM). It does not interact with androgen receptors at all. MK-677 is a non-peptide growth hormone secretagogue — it activates the ghrelin receptor (GHSR) to stimulate the pituitary gland to release more growth hormone. It is frequently mislabeled as a SARM in online communities and by supplement marketers, but this is pharmacologically incorrect.
Is MK-677 legal?
MK-677 is not a controlled substance in the United States — possession is not criminalized. However, it is not FDA-approved for any medical indication and cannot be legally marketed as a dietary supplement (it does not meet the definition of a dietary ingredient under DSHEA). The FDA has placed MK-677 on the Category 2 bulk drug substances list, which prevents compounding pharmacies from preparing it as a prescription medication. It is currently available only as a research compound.
Can I get a MK-677 prescription right now?
No. MK-677 is FDA Category 2, which prohibits compounding pharmacies from preparing it in any form. No legal prescription pathway exists in the United States as of April 2026. HHS has announced intent to reclassify certain Category 2 compounds to Category 1, which could potentially restore compounding access, but formal FDA rulemaking has not been published.
What is Category 2 vs Category 1?
The FDA categorizes bulk drug substances used by compounding pharmacies. Category 1 substances can be compounded by licensed 503A and 503B pharmacies with a valid prescription. Category 2 substances are restricted — compounding pharmacies cannot prepare them. MK-677 is currently Category 2. If reclassified to Category 1, compounding pharmacies could legally prepare MK-677 with a physician's prescription.
Could MK-677 be reclassified to Category 1?
HHS Secretary Kennedy announced on February 27, 2026, intent to reclassify 14 Category 2 peptides and compounds to Category 1. While MK-677 is technically not a peptide, it is included in the broader Category 2 compound list under discussion. Formal FDA rulemaking has not been published, and no official timeline has been announced. The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled meetings to review Category 2 compounds, but the outcome is not predetermined.
Is MK-677 banned in sports?
Yes. MK-677 is prohibited by WADA (World Anti-Doping Agency) under the S2 category (peptide hormones, growth factors, and related substances) and by the NCAA. Athletes subject to drug testing will test positive for ibutamoren metabolites. A potential Category 1 reclassification would not change its banned status in competitive athletics.
How is MK-677 different from GH peptides like CJC-1295 or GHRP-6?
MK-677 is an oral, non-peptide compound. GH-releasing peptides like CJC-1295, GHRP-6, and ipamorelin are injectable peptides that must be reconstituted and administered subcutaneously. MK-677 activates the ghrelin receptor (GHSR), while CJC-1295 activates the GHRH receptor and GHRPs activate the GHS receptor. The end result — increased GH release — is similar, but the route, mechanism, and convenience differ significantly.
Does MK-677 require post-cycle therapy (PCT)?
No. MK-677 does not suppress natural hormone production and does not require PCT. It stimulates your body's own GH release rather than replacing it. This is different from anabolic steroids and SARMs, which suppress the hypothalamic-pituitary-gonadal axis and typically require PCT to restore natural testosterone production.
Can women take MK-677?
MK-677 has been studied in both men and women in clinical trials, including postmenopausal women for bone density. The compound works through the ghrelin/GH axis, which is present in both sexes. Dosing is generally the same. Women should be aware of the same side effects — appetite increase, water retention, and insulin sensitivity changes. Clinical trial data in postmenopausal women showed increased bone turnover markers consistent with bone formation.
How long does it take for MK-677 to work?
GH and IGF-1 elevation occurs within the first dose — measurable within hours. Subjective effects on sleep quality are typically noticed within the first week. Body composition changes (lean mass, recovery) develop gradually over 4–12 weeks with consistent use. Bone density effects require 6–18 months of sustained use to be measurable.